Physician profile
Carl Leding
NPI 1912991381
$2,438.40
in general payments reported to CMS, 2019-2025
15 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $45.64 · 2021: $235 · 2022: $443 · 2023: $342 · 2024: $576 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.57 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $991.15 | 2019-2025 | |
| Abbott Laboratories | $226.31 | 2019-2024 | Aveir |
| Pfizer INC. | $201.17 | 2022-2025 | |
| Biotronik INC. | $166.54 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $142.14 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $128.77 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $120.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $93.73 | 2019-2025 | Farxiga |
| Amgen INC. | $76.18 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $71.07 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $69.73 | 2019-2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $66.53 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.49 | 2024-2025 | Jardiance |
| Inari Medical, INC. | $28.19 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Scpharmaceuticals INC. | $13.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Leding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.